PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Dulaglutide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist given as a once-weekly subcutaneous injection. · pmid:31189511

History

In the REWIND trial of 9,901 people with type 2 diabetes followed for a median 5.4 years, dulaglutide reduced the composite of non-fatal heart attack, non-fatal stroke or cardiovascular death compared with placebo (hazard ratio 0.88). · pmid:31189511

In the head-to-head AWARD-6 trial, once-weekly dulaglutide lowered HbA1c by 1.42% against 1.36% for once-daily liraglutide over 26 weeks. · pmid:25018121

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Dulaglutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. (2014) · establishedDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. (2019) · established20142019

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Dulaglutide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. · pmid 25018121 · 2014
    • Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. · pmid 31189511 · 2019
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.